5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

Hickok, Jane T.; Roscoe, Joseph A.; Morrow, Gary R.; Bole, Christopher W.; Zhao, Hongwei; Hoelzer, Karen L.; Dakhil, Shaker R.; Moore, Timothy M.; Fitch, Tom R.

doi:10.1016/s1470-2045(05)70325-9

Cited by 100 publications

(64 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The home-record questionnaire enables the patient to note nausea, vomiting, and use of antiemetic drugs and was used in our prior URCC CCOP protocol examining DN (see Introduction). 17 Every day is divided into four segments (morning, afternoon, evening, and night), and patients report the severity of nausea and number of vomiting episodes for the periods of that day. Severity of nausea was assessed by use of a 7-point semantic rating scale, ranging from 1 (not at all nauseated) to 7 (extremely nauseated).…”

Section: Assessmentsmentioning

confidence: 99%

Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

Roscoe

Heckler

Morrow

et al. 2012

JCO

View full text Add to dashboard Cite

Purpose We conducted a double-blind randomized clinical trial of the following four regimens for controlling delayed nausea (DN): group 1: palonosetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3; group 2: granisetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3; group 3: aprepitant + palonosetron + dexamethasone on day 1 with aprepitant + dexamethasone on days 2 and 3; and group 4: palonosetron + dexamethasone on day 1 with prochlorperazine + dexamethasone on days 2 and 3. Patients and Methods Chemotherapy-naive patients received doxorubicin, epirubicin, cisplatin, carboplatin, or oxaliplatin. The primary end point was average nausea assessed four times daily on days 2 and 3. Primary analyses were whether nausea control would be improved by using palonosetron versus granisetron on day 1 (group 1 v group 2); by adding dexamethasone on days 2 and 3 (group 1 v group 4); and by using aprepitant versus prochlorperazine (group 3 v group 4). Statistical significance was set at P = .017. Results Two hundred thirty-four, 234, 241, and 235 evaluable patients were accrued to groups 1, 2, 3, and 4, respectively. Adjusted mean differences for the three planned analyses were as follows: palonosetron versus granisetron: −0.01 (95% CI, −0.23 to 0.20; P = .72); adding dexamethasone on days 2 and 3: 0.20 (95% CI, −0.02 to 0.41; P = .01); and using aprepitant versus prochlorperazine: −0.03 (95% CI, −0.24 to 0.19; P = .56). Conclusion The addition of dexamethasone on days 2 and 3 reduced DN. Palonosetron and granisetron have similar effects on DN. The beneficial effect of adding aprepitant for control of DN was the same as adding prochlorperazine.

show abstract

Section: Assessmentsmentioning

confidence: 99%

Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

Roscoe

Heckler

Morrow

et al. 2012

JCO

View full text Add to dashboard Cite

show abstract

“…1), (3aS)-2-[(S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benz [de]isoquinolin-1-one hydrochloride, is a pharmacologically distinct and highly selective, secondgeneration 5-hydroxytryptamine type-3 (5-HT3) receptor antagonist approved for prevention of chemotherapy-and radiotherapy-induced nausea and vomit (CINV) after highly emetogenic chemotherapy. [1][2][3][4] Chemotherapy-and radiotherapyinduced nausea and vomit will have a series of related complications if they lack control; these are the most feared adverse reactions in cancer patients. 5-HT3 receptor antagonized mainly through competing to block the release of 5-HT and 5-HT3 receptor-binding of digestive tract mucosa in order to have a role in anti-vomit treatment.…”

Section: Introductionmentioning

confidence: 99%

Enantioseparation of Palonosetron Hydrochloride by Capillary Zone Electrophoresis with High-concentration β-CD as Chiral Selector

et al. 2009

View full text Add to dashboard Cite

The enantioseparation of four stereoisomers of palonosetron hydrochloride (PALO) by capillary zone electrophoresis using high concentration β-CD as chiral selector was described in this study. For optimization of the method of enantioseparation, several parameters such as β-CD concentration, separation buffer pH and concentration, the types and concentration of organic modifiers, and the applied voltage were evaluated. The optimum conditions were obtained as follows: 30 mmol L -1 NaH2PO4 (pH 3.0) containing 150 mmol L -1 β-CD and 10% (v/v) methanol with an applied voltage of 15 kV. Under these conditions, baseline separation of the four PALO stereoisomers was achieved within 35 min, and the reproducibility (expressed as relative standard deviation, RSD) of the migration times and the peak areas were below 0.5, 2.5% (intra-day), and 1.9, 4.4% (inter-day), respectively. hydrochloride, is a pharmacologically distinct and highly selective, secondgeneration 5-hydroxytryptamine type-3 (5-HT3) receptor antagonist approved for prevention of chemotherapy-and radiotherapy-induced nausea and vomit (CINV) after highly emetogenic chemotherapy. 1-4 Chemotherapy-and radiotherapyinduced nausea and vomit will have a series of related complications if they lack control; these are the most feared adverse reactions in cancer patients. 5-HT3 receptor antagonized mainly through competing to block the release of 5-HT and 5-HT3 receptor-binding of digestive tract mucosa in order to have a role in anti-vomit treatment.Chiral drugs include a large proportion of drugs at present; they generate different pharmacological effects through combining with different stereo structure molecules in the body in the processes of drug absorption, distribution, metabolism and excretion. Consequently, the separation and measurement of chiral drugs have great significance in the pharmacokinetics, pharmacological and toxicological mechanisms as well as in quality control of chiral drugs. Palonosetron hydrochloride contains two chiral centers and four stereoisomers: (3aR, 2R), (3aS, 2S), (3aR, 2S) and (3aS, 2R), among which only (3aS, 2S) possesses pharmacological activity. 5 Therefore, it is necessary to establish an appropriate enantiomeric separation method for PALO.Capillary electrophoresis (CE) is now recognized as a powerful tool for enantioseparation due to its high separation efficiency, low operational cost, simplicity and versatility. [6][7][8][9][10] In CE, the enantioselectivity is based on the chiral selector, which is dissolved in the running buffer. During the last decade, various types of chiral selectors, such as cyclodextrins (CDs) and their derivatives, 11,12 crown ethers, 13 chiral surfactants, 14,15 polysaccharides, 16,17 macrocyclic antibiotics, 18 proteins, 19 and metal complexes 20,21 have been widely used in CE. Among them, CDs and their various derivatives are the most popularly used chiral selectors with about 90% of the applications. 10 CDs, which obtained from amylum enzymatic conversion, can form inclusion compounds with many ...

show abstract

“…[1][2][3] Nausea and vomiting (NV) are still among the most common, expected and feared side effects among patients receiving chemotherapy. [1][2][3] In fact, some cancer patients who experience chemotherapy-induced nausea and vomiting (CINV) will delay chemotherapy treatments and contemplate refusing future treatments because of fear of further NV. [1][2][3][4] Anticipatory nausea and vomiting (ANV) are also problems among chemotherapy patients.…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3] In fact, some cancer patients who experience chemotherapy-induced nausea and vomiting (CINV) will delay chemotherapy treatments and contemplate refusing future treatments because of fear of further NV. [1][2][3][4] Anticipatory nausea and vomiting (ANV) are also problems among chemotherapy patients. By the fourth treatment cycle, anticipatory nausea has been reported in up to 30% of patients who had nausea following earlier chemotherapy cycles, 5 while rates of anticipatory vomiting have been reported as high as 20%.…”

Section: Introductionmentioning

confidence: 99%

“…4,[8][9][10][11] A great deal of progress has been made in the effective management of acute CINV, however delayed CINV and nausea alone remain substantial problems. 1,2 The purpose of this chapter is to provide an overview of the patho-psychophysiology of CINV, the recommended guidelines for standard treatment, and highlight newer targeted treatment approaches.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy-induced Nausea and Vomiting

Mustian

Darling

Janelsins

et al. 2008

Oncology &Amp; Hematology Review (US)

Self Cite

View full text Add to dashboard Cite

Despite treatment advances, nausea and vomiting, especially anticipatory nausea and vomiting, delayed nausea and vomiting and nausea alone, are still the most common, expected and feared side effects among patients receiving chemotherapy. Of the 70 to 80% of cancer patients who experience chemotherapy-induced nausea and vomiting many will delay or refuse future chemotherapy treatments and contemplate stopping all treatments because of fear of further nausea and vomiting. The purpose of this chapter is to provide an overview of the pathopsychophysiology of CINV, the recommended guidelines for standard treatment, and highlight newer targeted treatment approaches.

show abstract

5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

Cited by 100 publications

References 26 publications

Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

Enantioseparation of Palonosetron Hydrochloride by Capillary Zone Electrophoresis with High-concentration β-CD as Chiral Selector

Chemotherapy-induced Nausea and Vomiting

Contact Info

Product

Resources

About